BNET Industries

Market Cap:$144.0M
Last Fiscal Year Sales:$18.4M
  • Public
  • US
Dow Jones Description

We are a drug discovery and development company that is utilizing our strength in small molecule drug technologies to discover and develop medicines for the treatment of cancer and related conditions. Our lead product candidate, IPI-504 (retaspimycin hydrochloride) is an intravenously-administered small molecule inhibitor of heat shock protein 90, or Hsp90. Hsp90 is a central component of the cellular chaperone systema system that supports and stabilizes cancer-causing proteins such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. Thus, Hsp90 chaperone inhibition may represent a significant yet currently unaddressed strategy for treating patients with cancer. We are evaluating IPI-504 in multiple clinical trials, including an international Phase 2 clinical trial of IPI-504 in combination with Herceptin ® (trastuzumab) in patients with HER2-positive metastatic breast cancer, the Phase 2 portion of a Phase 1/2 clinical trial of IPI-504 in patients with advanced non-small cell lung cancer, or NSCLC, and a Phase 1 clinical trial of IPI-504 in combination with Taxotere ® (docetaxel) in patients with advanced solid tumors. We expect to commence an additional trial of IPI-504 in early 2010. ...

Number of Employees 161
Contact Information

780 Memorial Dr

Cambridge, Massachusetts 02139

infi.com

(617) 453-1000

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Infinity Pharmaceuticals Appoints Industry Veteran Thomas Lynch to its Board of Directors

    10/24/09 - Board Member - Entering - View Story

  • Infinity Appoints Lynch To Board

    10/08/09 - Board Member - Entering - View Story

News & Analysis

infinity pharmaceuticals inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Steven H. Holtzman President
David S. Grayzel Vice President, Clinical Dev & Medical Affairs
Gerald E. Quirk General Counsel & Vice President
James L Wright Vice President, Pharmaceutical Dev
Jeffrey K Tong Vice President, Corp & Product Dev
John J Keilty Vice President, Information Technology and Informatics
Michael S Curtis Vice President, Pharmaceutical Development
Steven J. Kafka Vice President
Vito J. Palombella Vice President, Drug Discovery
Dr Frank Moss Co-Founder
Eric S Lander Co-Founder
Roxanne Duan Founder
Arnold J. Levine Lead Research & Development Director
Christian C Fritz Senior Director, Cancer Biology
Christine P. Bellon Director, Intellectual Property & Senior Patent Counsel
Jeanette W Kohlbrenner Senior Director, Human Resources
Margaret A. Read Senior Director, Cancer Biology
Christopher M Lindblom Principal Accounting Officer
Harry F. Hixson Director

Board of Directors

Name (plus bio) Position
Vicki L. Sato Lead Outside Director and Chair of Infinity's Compensation Committee
Anthony B. Evnin Board of Directors
Ian F. Smith Chair
Michael C. Venuti Chair of Infinity's Research and Development Committee
D. Ronald Daniel Board of Directors
Franklin H. Moss Board of Directors
Herm Rosenman Board of Directors
James Tananbaum Board of Directors
Martin Babler Board of Directors
Patrick Lee Board of Directors

Steven H. Holtzman , age 55, has served as our Chief Executive Officer and Chair of our board of directors since September 2006, and as our president from October 2007 to October 2008. Mr. Holtzman is also a co-founder of Old Infinity and served as its Chief Executive Officer and as Chair of its board of directors from inception in 2001 through completion of the reverse merger. Mr. Holtzman has also served as President of Old Infinity from July 2001 to February 2006. From 1994 to 2001, Mr. Holtzman served as Chief Business Officer of Millennium Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. From 1996 to 2001, Mr. Holtzman served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. Prior to joining Millennium Pharmaceuticals, Inc., from 1986 to 1994, Mr. Holtzman was a founder and Executive Vice President of DNX Corporation, a publicly-traded biotechnology company. Mr. Holtzman is a director of Anadys Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and a trustee of the Berklee College of Music. Mr. Holtzman received a B.A. in Philosophy from Michigan State University and a B.Phil. in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Organization Position Status
Infinity Pharmaceuticals, Inc Chair and Chief Executive Officer Current
Infinity Pharmaceuticals, Inc President Current
University of Oxford Chief Current
Corpus Christi College Chief Current
The Convergence Forum Founder Current
Verosound Co-Founder, Co-Founder Current
Berklee College of Music Trustee Current
Nantucket Conference Current
Life Sciences, Inc. Board of Directors Current
Anadys Pharmaceuticals, Inc. Board of Directors Current
Archemix Corp Board of Directors Current
Berklee College of Music Board of Directors Current
Millennium Pharmaceuticals, Inc. Chief Business Officer Former
Infinity Pharmaceuticals, Inc Founder Former
DNX Corporation Founder Former
Corpus Christi College Founder Former
Corpus Christi College Instructor Former
Millennium Pharmaceuticals, Inc. Leader Former
Infinity Pharmaceuticals, Inc Executive Officer Former
Rigid Building Systems Ltd. Former
Biotechnology Industry Organization Chairman Former
University of Oxford Graduate Degree In Philosophy Former
Michigan State University B.A. In Philosophy Former

David S. Grayzel, M.D., is Vice President, Clinical Development and Medical Affairs. Dr. Grayzel is currently responsible for leading Infinity's clinical research efforts and oversees both clinical development and clinical operations. Prior to Infinity, he was at Dyax Corp., a biopharmaceutical company focused on antibody and protein therapeutics. At Dyax, he was Director of Corporate Development and Business Operations, responsible for marketing and commercialization strategy for therapeutic products in the development pipeline, including late-stage clinical trials as well as business initiatives for in-licensing of targets, out-licensing of late-stage compounds, and co-development partnerships. Dr. Grayzel obtained his medical degree at Harvard Medical School and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital. Prior to his medical training, Dr. Grayzel was a Curriculum Director at Stanford University Medical Center, creating their first case-based medical ethics curriculum. He holds a B.A. with honors from Stanford University.

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President, Clinical Dev & Medical Affairs Current
Dyax Corp. Director of Corporate Development Former
Stanford University Medical Center Curriculum Director Former
Massachusetts General Hospital Residency Former
Stanford University B.A. With Honors Former
Harvard Medical School Degree Former

Gerald E. Quirk, Esq., is Vice President and General Counsel. He is responsible for Infinity’s legal and compliance initiatives, as well as the company’s intellectual property portfolio. He has extensive experience representing biotechnology companies in connection with securities offerings and SEC compliance activities, mergers and acquisitions, licensing and other collaboration agreements, and product commercialization initiatives. Prior to joining Infinity, Mr. Quirk served in a number of progressively responsible legal and business development positions at Genzyme Corporation, having most recently been responsible for the provision of all non-patent legal services to Genzyme’s oncology, cardiovascular, and medical device businesses. Mr. Quirk began his career as an associate in the business law department and biotechnology practice group at Palmer & Dodge LLP, a Boston law firm. Mr. Quirk earned his J.D. from Northeastern University School of Law, an Ed.M. in Educational Administration from Harvard University, and a B.A. in Political Science from Swarthmore College.

Organization Position Status
Infinity Pharmaceuticals, Inc General Counsel & Vice President Current
Palmer Dodge Inc. Associate Former
Genzyme Corporation Former
Northeastern University School of Law J.D. Former
Swarthmore College B.A. In Political Science Former
Harvard University Educational Administration Former

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President, Pharmaceutical Dev Current

Jeffrey K. Tong, Ph.D., is Vice President, Corporate and Product Development. Dr. Tong is responsible for leading Infinity's product development teams and corporate development efforts. Prior to joining Infinity, Dr. Tong was with the Palo Alto office of McKinsey & Company, where his work focused in healthcare with projects for leading biotechnology and pharmaceutical companies in areas of new business building, technology spinouts, and venture investing. Prior to McKinsey, Dr. Tong was a founding researcher of the Harvard Center for Genomics Research. Dr. Tong received his educational training at the interface of molecular biology, synthetic chemistry, and medicine. His previous research interest was in the area of histone deacetylase biology where he was involved with multiple teams in the identification and functional characterization of novel histone deacetylases and their macromolecular complexes. Dr. Tong holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University under the direction of Professor Stuart Schreiber.

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President, Corp & Product Dev Current
Harvard College M.S. Degrees Former
Harvard Medical School M.S. Degrees Former
Harvard University A.B. Former
Harvard Medical School A.B. Former
Harvard College A.B. Former
Harvard Medical School Degree Former
Harvard College Degree Former

John J. Keilty is Vice President, Information Technology and Informatics. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity, Mr. Keilty was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including Senior Manager of Molecular Research Services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Many of the developed software applications, algorithms and laboratory procedures were transferred to Millennium’s corporate partners as part of larger business collaborations. Before Millennium, Mr. Keilty worked in the Howard Hughes lab of Michael Green at University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing. Mr. Keilty holds a B.A. in biology from Clark University.

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President, Information Technology and Informatics Current
Infinity Pharmaceuticals, Inc Senior Director Former
Millennium Pharmaceuticals, Inc. Board of Directors Former
Clark University B.A. In Biology Former

Michael S. Curtis, Ph.D., is Vice President of Pharmaceutical Development with responsibility for manufacturing, formulation, and analytical characterization of Infinity's pre-clinical and clinical drug candidates. Prior to joining Infinity, Dr. Curtis was an Associate Director within the Pharmaceutical and Analytical Development group at Transkayotic Therapies (TKT, currently Shire) where he was responsible for analytical methods development and validation to support the registration of Elaprase® (idursulfase). Before TKT, Dr. Curtis was the Associate Director of Analytical Development at Syntonix Pharmaceuticals where he was involved with advancing the Transceptor® drug delivery technology and in particular its expansion as an oral delivery platform. Prior to Syntonix, he was a member of the Therapeutic Protein Research group at Genzyme working on the development and characterization of the enzyme replacement therapy Myozyme® (alglucosidase alfa). Dr. Curtis began his career at Bristol-Myers Squibb where he held positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril) and Taxol® (paclitaxel) and the early development of Orencia® (abatacept). Dr. Curtis received his B.S. in Biochemistry from the State University of New York College of Environmental Science and Forestry and his Ph.D. in Cell and Molecular Biology from Upstate Medical University.

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President, Pharmaceutical Development Current
Syntonix Pharmaceuticals, Inc. Associate Director of Analytical Development Former
Bristol-Myers Squibb Company Former
Upstate Medical University Ph.D. In Cell and Molecular Biology Former

Steven J. Kafka, Ph.D., is Vice President, Finance. Dr. Kafka oversees investor and public relations, financial planning and analysis, accounting, treasury, purchasing, and business operations. Dr. Kafka joined Infinity from Millennium Pharmaceuticals, where he was Senior Director, Finance. As leader of the Financial Planning and Analysis group at Millennium, he and his team were responsible for corporate business planning, financial management, and product portfolio strategy support. He also served as a member of the VELCADE® leadership team where he helped to establish and guide the product’s U.S. commercial strategy and operations and its global co-development strategy with partner Johnson & Johnson. Dr. Kafka worked for several years as a senior member of the life sciences practice of Strategic Decisions Group (SDG), a business strategy consulting firm, where he specialized in the pharmaceutical industry. His experience at SDG included leadership of portfolio integration efforts for the merger of two global pharmaceutical firms, establishment of portfolio strategy and ongoing management for the Japanese assets of a global biopharmaceutical firm, and product development strategy projects across a host of therapeutic areas.

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President Current
Millennium Pharmaceuticals, Inc. Senior Director Former
Johnson & Johnson Member Former
Rigid Building Systems Ltd. Former
Sdg Corporation Former

Vito J. Palombella, Ph.D., is Vice President, Drug Discovery. Prior to joining Infinity, Dr. Palombella was at Syntonix Pharmaceuticals. At Syntonix he was Director of Molecular Biology and Protein Chemistry, responsible for improving and expanding its core Fc receptor-mediated drug delivery technology. Before joining Syntonix, Dr. Palombella was Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, which he joined through its acquisition of LeukoSite (where he held the same title) in 1999. Prior to its acquisition by LeukoSite, Dr. Palombella held a number of positions at ProScript, Inc. (between 1994 and 1999). While at ProScript, LeukoSite, and Millennium, Dr. Palombella was involved in the discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. He also managed a number of additional projects, including research into NF-?B regulation. Dr. Palombella received a B.S. in Microbiology from Rutgers University and his M.S. and Ph.D. in Viral Oncology and Immunology from the New York University Medical Center. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Tom Maniatis.

Organization Position Status
Infinity Pharmaceuticals, Inc Vice President, Drug Discovery Current
Millennium Pharmaceuticals, Inc. Senior Director of Cell and Molecular Biology Former
Syntonix, Inc Director of Molecular Biology Former
Harvard University Fellow Former
Proscript Former
LeukoSite, Inc. Former
Syntonix Pharmaceuticals, Inc. Former
New York University Medical Center Ph.D. In Viral Oncology and Immunology Former
New York University Medical Center M.S. Former
Rutgers University B.S. In Microbiology Former

Frank Moss, Ph.D., is a co-founder of Infinity. Since 1998, Dr. Moss has been President of Strategic Software Ventures, a firm that nurtures enterprise software startup companies; since February 2006, Dr. Moss has served as Director of The Media Lab and Weisner Professor of Media Arts and Sciences at the Massachusetts Institute of Technology. From 1991 - 1996, Dr. Moss served as Chief Executive Officer and Chairman of Tivoli Systems, a private software company sold to IBM in 1996. Prior to joining Tivoli Systems, Dr. Moss held a variety of positions with Lotus Development, Stellar Computer, Apollo Computer, and IBM Research. Dr. Moss received a B.S. in Aerospace and Mechanical Sciences from Princeton University and an S.M. and Ph.D. in Aeronautics and Astronautics from the Massachusetts Institute of Technology.

Organization Position Status
Infinity Pharmaceuticals, Inc Co-Founder Current
Nantucket Conference Current
Cylant, Inc. Current
The Convergence Forum Board of Directors Current
Infinity Pharmaceuticals, Inc Board of Directors Current
The Advisory Council Board of Directors Current
The Convergence Guide Board of Directors Current
Tivoli Systems CEO Former
Systinet Corporation co-founder Former
Onaro, Inc. Former
Computer Reseller News Former
Bowstreet, Inc. Former
Lotus Development Corporation Former
International Business Machines Corporation Former
Tivoli Systems later chairman Former
Massachusetts Institute of Technology doctorate in Aeronautics and Astronautics Former
Princeton University B.S. in Aerospace and Mechanical Sciences Former

Eric S. Lander, Ph.D., is a co-founder of Infinity. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 - 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.

Organization Position Status
Infinity Pharmaceuticals, Inc Co-Founder Current
Access Excellence Associate Professor of Biology and Director of the Center for Genome Research Current
Harvard Medical School Professor of Systems Biology Current
The Sacred Balance Current
Backup-Reports.Com Current
Entertainment Industry Foundation Board of Directors Current
Broad Medical Research Program Board of Directors Current
Millennium Pharmaceuticals, Inc. Board of Directors Current
Genetics Society of America Board of Directors Current
Whitehead Institute for Biomedical Research Board of Directors Current
National Academy of Sciences Board of Directors Current
Infinity Pharmaceuticals, Inc Board of Directors Current
National Academy of Sciences Member Current
Genetics Society of America Member Current
Sciences, Inc Board of Directors Former
University of Oxford Ph.D. In Mathematics Former
Princeton University B.A. In Mathematics Former
Sciences, Inc Member Former
Whitehead Institute for Biomedical Research Member Former

Organization Position Status
National Cancer Institute Former
Women In Bio Co Board of Directors Current
The University of California, San Francisco Ph.D. Degree Former

Arnold J. Levine, Ph.D., is a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 - 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 - 1996. Dr. Levine also serves as a Director of Theravance, Inc. and Applera Corporation, publicly traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from the University of Pennsylvania.

Organization Position Status
Infinity Pharmaceuticals, Inc Lead Research & Development Director Current
Cancer Institute Prof Current
Institute for Advanced Studies Visiting Professor Current
The Cancer Institute of New Jersey Professor Current
Celera Diagnostics, LLC Current
Celera Genomics Current
Bg Medicine, Inc. Co-Chairman Current
Theravance, Inc. Chairperson Current
Applied Biosystems Group Board of Directors Current
Exsar Corporation Board of Directors Current
National Academy of Sciences Board of Directors Current
Avidimer Therapeutics, Inc. Board of Directors Current
Theravance, Inc. Board of Directors Current
The Ellison Medical Foundation Board of Directors Current
Functional Genetics, Inc. Board of Directors Current
Infinity Pharmaceuticals, Inc Board of Directors Current
Applera Corporation Director Current
Theravance, Inc. Committee Member Current
The Rockefeller University Chief Executive Officer Former
The Rockefeller University President Former
Princeton University Professor Former
The Rockefeller University Visiting Professor Former
Princeton University Chairman Former
University of Pennsylvania Ph.D. In Microbiology Former
University of Pennsylvania School of Medicine PhD In Microbiology Former
State University of New York at Binghamton B.A. Former
National Academy of Sciences member Former
United States Public Health Services (USPHS) Fellow Former

Organization Position Status
Infinity Pharmaceuticals, Inc Senior Director, Cancer Biology Current
Millennium Pharmaceuticals, Inc. Senior Scientist Former
University of Cologne Doctor of Philosophy, Genetics, Molecular Biology Former

Organization Position Status
Infinity Pharmaceuticals, Inc Director, Intellectual Property & Senior Patent Counsel Current

Jeanette W. Kohlbrenner is Senior Director, Human Resources. She is responsible for Infinity’s human resource and organizational development functions. Ms. Kohlbrenner joined Infinity with over 15 years of experience in senior human resource roles with life science and medical device companies, ranging from start-up to fully commercial, global organizations. Prior to joining Infinity, Ms. Kohlbrenner was the Business Unit Director of Human Resources for Cambrex Biosciences, with responsibilities for pharmaceutical development and manufacturing locations in the United States. Before Cambrex, Ms. Kohlbrenner was at Syntonix Pharmaceuticals, where she was the Director of Human Resources and a key member of the senior team, working to build the company. Ms. Kohlbrenner also held human resource roles with Genetics Institute/Wyeth Pharmaceuticals, and Hewlett-Packard’s Medical Device business (now Philips Medical). Early in her career, Ms. Kohlbrenner was a compensation and performance management consultant with William Mercer, a global leader in human resource consulting. Ms. Kohlbrenner holds an M.B.A. from Babson College and a B.A. in Mathematics from Holy Cross.

Organization Position Status
Infinity Pharmaceuticals, Inc Senior Director, Human Resources Current
Syntonix Pharmaceuticals, Inc. Former
Babson College M.B.A. Former
Holy Cross B.A. In Mathematics Former

Organization Position Status
Infinity Pharmaceuticals, Inc Senior Director, Cancer Biology Current
Harvard Medical School Instructor Former
Proscript Former
Millennium Pharmaceuticals, Inc. Director Former
Vanderbilt University Ph.D. Former
The University of Tennessee B.S. In Biology, Continuing on To Former
Vanderbilt University Postdoctoral, Molecular Microbiology Former

Vicki L. Sato, Ph.D., Lead Outside Director and Chair of Infinity's Compensation Committee, is currently a professor at Harvard University. From 1992 - 2005, Dr. Sato held various positions with Vertex Pharmaceuticals, Inc., a publicly traded pharmaceutical company, most recently serving as President from 2000 - 2005. Prior to joining Vertex Pharmaceuticals, Inc., from 1984 - 1992, Dr. Sato held various positions with Biogen, Inc., a publicly traded biotechnology company, most recently serving as Vice President of Research and a member of the Scientific Advisory Board. Since 1993, Dr. Sato has served on the Board of Tutors, Department of Biochemistry and Molecular Biology at Harvard University, and also served as an Assistant Professor and Associate Professor in the Department of Biology at Harvard University from 1975 - 1983. Dr. Sato is a business advisor to Atlas Ventures, a venture capital firm, and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato serves as an overseer of the Isabella Stewart Gardner Museum and is a trustee of Jose Mateo’s Ballet Theatre. Dr. Sato serves as a director of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc., publicly traded biopharmaceutical companies, Perkin-Elmer, Inc., a diversified company with businesses in the life and analytical sciences and optoelectronics, and Avila Therapeutics, a private biotechnology company. Dr. Sato received an A.B. in Biology from Radcliffe College and an M.A. and Ph.D. in Biology from Harvard University.

Organization Position Status
Infinity Pharmaceuticals, Inc Lead Outside Director and Chair of Infinity's Compensation Committee Current
Bristol-Myers Squibb Company Professor of Management Practice at the Harvard Business School and Professor Current
Harvard Business School Professor of Management Practice Current
Alnylam Pharmaceuticals, Inc. Professor of Management Practice Current
Harvard University Professor of Molecular and Cell Biology Current
Vertex, Inc. Current
Alnylam Pharmaceuticals, Inc. Chair Current
Ballet Theatre Board of Directors Current
Alnylam Pharmaceuticals, Inc. Board of Directors Current
Bioventures Investors Board of Directors Current
Tutors LLC Board of Directors Current
Bristol-Myers Squibb Company Board of Directors Current
Vertex Pharmaceuticals Incorporated President Former
Biogen, Inc. Former
Harvard University M.A. Former
Radcliffe College A.B. In Biology Former

Organization Position Status
Infinity Pharmaceuticals, Inc Principal Accounting Officer Current
Infinity Pharmaceuticals, Inc Board of Directors Current

Anthony B. Evnin, Ph.D. , a director since October 2006, is a General Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He is currently a member of the Board of Directors of Icagen, Inc., Infinity Pharmaceuticals, Inc and Sunesis Pharmaceuticals, Inc., as well as being on the Board of Directors of a number of private companies. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Organization Position Status
Venrock Associates Managing General Partner Current
Pharmos Corporation Managing General Partner, Venrock Associates Current
Renovis, Inc. Board of Directors Current
Infinity Pharmaceuticals, Inc Board of Directors Current
Vela Pharmaceuticals, Inc. Current
Infinity Pharmaceuticals, Inc Chair of Infinity's Nominating and Governance Committee Current
Venrock Associates Board of Directors Current
Acceleron Pharma Inc Board of Directors Current
The Rockefeller University Board of Directors Current
Uv Partners Board of Directors Current
Coley Pharmaceutical Group Inc. Board of Directors Current
Icagen, Inc. Board of Directors Current
Alta Partners Director Current
Memory Pharmaceuticals Corp. Board of Directors Current
Pharmos Corporation Director Current
Altea Therapeutics Board Member Current
Metabolex, Inc. Board Member Current
Aveo Pharmaceuticals, Inc. Board of Directors Current
Cancer Immunity Board of Directors Current
Triangle Pharmaceuticals, Inc. Board of Directors Current
Celladon Director Current
Caliper Technologies Board of Directors Current
Syntonix Pharmaceuticals, Inc. Director Current
Sonic Innovations, Inc. Board of Directors Current
Union Carbide Corporation Research Scientist Former
Gilead Sciences, Inc. Former
Sunesis Pharmaceuticals, Inc. Board of Directors Former
IDEXX Laboratories, Inc. Investor Former
Sepracor Inc. Investor Former
Triangle Pharmaceuticals, Inc. Investor Former
Sonic Innovations, Inc. Investor Former
Centocor, Inc. Investor Former
Caliper Life Sciences, Inc. Investor Former
IDEC Pharmaceuticals Investor Former
Massachusetts Institute of Technology Ph.D. in chemistry Former
Massachusetts, Inc. Ph.D. In Chemistry Former
Princeton University A.B. Former
Memory Pharmaceuticals Corp. member Former

Ian Smith joined Vertex in November 2001. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001. As Vertex’s CFO, Mr. Smith holds responsibility for a wide variety of core functions at Vertex, including Finance, Strategic Communications, Information Systems and Operations. Mr. Smith is also a member of the Executive Team at Vertex. Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University. Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute. Mr. Smith is a member of the Board of Directors of Acorda Therapeutics, Inc, Epix Pharmaceuticals, Inc. and TolerRx Inc. Additionally, he is a board member of the Massachusetts Biotechnology Council and is Chair of its Policy Committee.

Organization Position Status
Vertex Pharmaceuticals Incorporated Executive Vice President and Chief Financial Officer Current
Vertex, Inc. Executive Vice President Current
Infinity Pharmaceuticals, Inc Chair Current
Acorda Therapeutics, Inc. Board of Directors Current
TolerRx, Inc. Board of Directors Current
Predix Pharmaceuticals Holdings, Inc. Board of Directors Current
Vertex Pharmaceuticals Incorporated Board of Directors Current
Prohost Biotechnology Board of Directors Current
American Institute of Certified Public Accountants Member Current
Vertex, Inc. Chief Financial Officer Former
Vertex Pharmaceuticals Incorporated Senior Vice President Former
Vertex, Inc. Senior Vice President Former
Vertex, Inc. Vice President Former
Life Science!, Inc Partner Former
Ernst & Young partner Former
Manchester Metropolitan University B.A. with honors in accounting Former

Array

Organization Position Status
University of California Adjunct Prof of Chemistry Current
Global Health Limited Executive Scientific Advisor Current
University of California, San Francisco Adjunct Professor of Chemistry Current
Infinity Pharmaceuticals, Inc Chair of Infinity's Research and Development Committee Current
Innovative Salon Solutions Board of Directors Current
Discovery Partners International, Inc. Board of Directors Current
Infinity Pharmaceuticals, Inc Acting Chief Executive Officer Former
Discovery Partners International, Inc. Chief Executive Officer Former
Infinity Pharmaceuticals, Inc Chief Scientific Officer Former
Axys Pharmaceuticals Chief Technical Officer Former
Axys Pharmaceuticals Senior Vice President, Research and Preclinical Development Former
Axys Pharmaceuticals General Manager Former
Infinity Pharmaceuticals, Inc Board of Directors Current
Dartmouth College A.B. Former

Organization Position Status
Infinity Pharmaceuticals, Inc Board of Directors Current

Organization Position Status
Infinity Pharmaceuticals, Inc Board of Directors Current

Array

Organization Position Status
Sequenom, Inc. Chairman of the Board of Directors Current
San Diego Opera Member of the Board Current
Discovery Partners International, Inc. Board of Directors Current
Signal Pharmaceuticals, LLC Director Current
Arena Pharmaceuticals, Inc. Director Current
Infinity Pharmaceuticals, Inc Director Current
Arena Pharmaceuticals, Inc. Member Current
Braincells, Inc. Chief Executive Officer Former
Amgen Inc. President and Chief Operating Officer and Member Former
Braincells, Inc. Co-Founder Former
Abbott Laboratories Former
Discovery Partners International, Inc. Chairman Former
Sequenom, Inc. Board of Directors Current
University of Chicago M.B.A. Former
Purdue University B.S. In Chemical Engineering Former
Amgen Inc. Member Former

Organization Position Status
Gen-Probe Inc. Senior Vice President, Finance and Chief Financial Officer Current
ARYx Therapeutics Inc Board of Directors Current
Discovery Partners International, Inc. Board of Directors Current
Infinity Pharmaceuticals, Inc Board of Directors Current
Radnet Management Inc. Chief Executive Officer Former
Radnet Management Inc. President Former
PricewaterhouseCoopers partner Former
Cooper's Inc. Partner Former
Wharton Graduate School of the University of Pennsylvania M.B.A. In Finance Former
Wharton Graduate School of the University of Pennsylvania B.B.A. In Finance Former
Pace University B.B.A. In Finance Former

Organization Position Status
Novavax, Inc. Managing Director, Prospect Venture Partners Current
Amira Pharmaceuticals Inc Managing Director and Co-Founder of Prospect Venture Partners II and III Current
Prospect Venture Partners Managing Director Current
Vitae Pharmaceuticals, Inc Co-Founder Current
Golden Gate Chapter Officer Current
Young Presidents' Organization Officer Current
Novavax, Inc. Director Current
Cornerstone Therapeutics, Inc. Director Current
Young Presidents' Organization Board of Directors Current
Bird Flu Guardian Board of Directors Current
Vanda Pharmaceuticals Inc. Director Current
Infinity Pharmaceuticals, Inc Board of Directors Current
Vitae Pharmaceuticals, Inc Board of Directors Current
Roxro Pharma, Inc Board of Directors Current
Amira Pharmaceuticals Inc Board of Directors Current
Young Presidents' Organization Member Current
GelTex Pharmaceuticals Acting CEO Former
Infinity Pharmaceuticals, Inc Acting CEO Former
Theravance, Inc. Chief Executive Officer Former
Geltex, LLC Founder Former
Infinity Pharmaceuticals, Inc Founder Former
GelTex Pharmaceuticals Co-Founder Former
Prospect Venture Partners Co-Founder Former
Theravance, Inc. Founder Former
Prospect Venture Partners Managing Partner Former
Sierra Ventures Partner Former
Infinity Pharmaceuticals, Inc Manager Former
Merck & Co. Inc. senior product manager Former
Amerigroup Corporation Investor Former
Healtheon Investor Former
Harvard University MD Former
Harvard Medical School M.D. Former
Harvard University MBA Former
Yale University Undergraduate Degree Former
Harvard University Undergraduate Degree Former

Organization Position Status
Talima President and Chief Executive Officer Current
Infinity Pharmaceuticals, Inc Board of Directors Current

Patrick Lee is a General Partner of Ares Life Sciences, an investment firm, since February 2009. Prior to Ares Life Sciences, Mr. Lee was a General Partner at Advent Venture Partners, a venture capital firm, where he was employed since 1999. Before Advent Venture Partners, from 1989 - 1999, Mr. Lee held various positions with Rhone-Poulenc Rorer in the U.S., and Rhone-Poulenc in Paris, France, where he was most recently Group Vice President for Mergers and Acquisitions. Prior to that he had been with Baxter International and Booz Allen Hamilton. Mr. Lee received a B.A. in Biology from Vassar College and an M.B.A. from the Stanford Graduate School of Business.

Organization Position Status
Infinity Pharmaceuticals, Inc Board of Directors Current
Conatus Pharmaceuticals Inc Board of Directors Current
Speciality European Pharma Limited Board of Directors Current
RhOne-Poulenc Group Vice President for Mergers & Acquisitions Former
Advent Venture Partners Llp. General Partner Former
Rhone-Poulenc Rorer Former
Advent Inc. Former
Booz Allen Hamilton, Inc. Former
Stanford Graduate School of Business M.B.A. Former
Vassar College B.A. In Biology Former

Executive News

  • Satori Pharmaceuticals names new board member

    TradingMarkets - 9/05/09 - View Story

  • Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors

    Globe Investor - 9/03/09 - View Story

advertisement
     INFI $5.54 +0.04 (0.73% )
Average Volume 37,454
Shares Outstanding 26.16M
Market Cap 144.9M
Year High 8.985
Year Low 4.77
Earnings Per Share 1.10
P/E Ratio 5.04
Dividend N/A
Yield N/A
advertisement
Click Here